ACURA PHARMACEUTICALS INC's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on ACURA PHARMACEUTICALS market sentiment investors' perception of the future value of ACURA. Let us look at a few aspects of ACURA technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Acura Pharmaceuticals. In general, sophisticated investors focus on analyzing Acura Pharmaceuticals stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Acura Pharmaceuticals's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Acura Pharmaceuticals's intrinsic value. In addition to deriving basic predictive indicators for Acura Pharmaceuticals, many experienced traders also check how macroeconomic factors affect Acura Pharmaceuticals price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, frequently view the market will even out over time. This tendency of Acura Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Acura Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acura Pharmaceuticals. Your research has to be compared to or analyzed against Acura Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Acura Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Acura Pharmaceuticals.
Watch out for price decline
Please consider monitoring Acura Pharmaceuticals on a daily basis if you are holding a position in it. Acura Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Acura Pharmaceuticals stock to be traded above the $1 level to remain listed. If Acura Pharmaceuticals otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Acura Pharmaceuticals's Liquidity
Acura Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance Acura Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acura Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Acura Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Acura Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Acura Pharmaceuticals's total debt and its cash.
Closer look at ACURA PHARMACEUTICALS Variance
ACURA PHARMACEUTICALS INC has current Variance of 108.34. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.
Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.
Variance | = | SUM(RET DEV)2 N |
| = | 108.34 |
SUM | = | Summation notation |
RET DEV | = | Actual returns deviation over selected period |
N | = | Number of points for the period |
Let's now compare ACURA PHARMACEUTICALS Variance to its closest peers:
| ACUR | 108.34 |
| EQ | 66.21 |
| NK | 36.31 |
| DMAC | 25.43 |
| DNLI | 16.22 |
Is ACURA PHARMACEUTICALS getting woozy?
Latest Skewness is up to -0.09. Price may fall again. As of the 26th of November, ACURA PHARMACEUTICALS shows the Mean Deviation of 7.34,
coefficient of variation of 3039.29, and Market Risk Adjusted Performance of 114.65. ACURA PHARMACEUTICALS INC
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices. Put another way, you can use this information to find out if the entity will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen
technical drivers for ACURA PHARMACEUTICALS INC, which can be compared to its rivals. Please confirm
ACURA PHARMACEUTICALS INC variance,
value at risk, as well as the
relationship between the Value At Risk and
skewness to decide if ACURA PHARMACEUTICALS INC is priced favorably, providing market reflects its regular price of 0.21 per share. As
ACURA PHARMACEUTICALS INC appears to be a penny stock we also recommend to validate its
total risk alpha numbers.
Our Final Take On ACURA PHARMACEUTICALS
While some other firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, ACURA PHARMACEUTICALS may offer a potential longer-term growth to retail investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor exit any shares of ACURA PHARMACEUTICALS at this time. The ACURA PHARMACEUTICALS INC risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ACURA PHARMACEUTICALS.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Acura Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com